Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sandoz Inc.

www.us.sandoz.com

Latest From Sandoz Inc.

Boehringer Bids To Go Beyond Slowing IPF

The family-owned German group is the market leader in idiopathic pulmonary fibrosis with Ofev but the big-selling drug has significant side effects and only slows, but does not stop, the progression of the disease. It is hoping that the Phase III-ready compound BI 1015550 will offer a significant improvement.

Respiratory Clinical Trials

Sandoz Launches First US Pirfenidone At-Risk After Court Triumphs

Sandoz has introduced the first generic version of Roche’s landmark treatment for idiopathic pulmonary fibrosis, Esbriet (pirfenidone), after downing the originator’s attempts to stymie its launch.

Launches Generic Drugs

US Federal Circuit Swats Attempt To Block Sandoz’s Pirfenidone

Sandoz won big earlier this year at the district court level following its submission of ANDAs referencing Genentech’s Esbriet (pirfenidone) treatments for idiopathic pulmonary fibrosis. The Roche subsidiary has failed in its attempts to secure an injunction pending appeal, while firing off on the district court for its earlier ruling.

Generic Drugs Intellectual Property

Forcefield Therapeutics Launched With ‘Gamechanger’ Goal For Post-MI Therapy

The newly launched biotech has a novel platform for discovering protective tissue factors and turning them into therapies,with heart failure prevention its first target.

Companies Cardiovascular
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
UsernamePublicRestriction

Register